Trial Profile
A Single-Arm, Open-Label, Two-Stage Phase II Study of the MEK 1/2 Inhibitor Trametinib in Men With Progressive Metastatic Castrate Resistant Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 May 2023
Price :
$35
*
At a glance
- Drugs Trametinib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 27 Apr 2023 Planned End Date changed from 31 Jan 2024 to 31 Jan 2025.
- 27 Apr 2023 Planned primary completion date changed from 31 Jan 2023 to 31 Jan 2024.
- 11 May 2022 Planned End Date changed from 31 Jan 2023 to 31 Jan 2024.